Expertise in
21
conditions

Dr. Karim S. Elsahwi

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
HMH - Obstetrics And Gynecology - Neptune
19 Davis Avenue, Floor 7, 
Neptune, NJ 
Expertise in
21
conditions
HMH - Obstetrics And Gynecology - Neptune
19 Davis Avenue, Floor 7, 
Neptune, NJ 

Overview

Karim Elsahwi is a Gynecologic Oncologist and an Oncologist in Neptune, New Jersey. Dr. Elsahwi is highly rated in 21 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Cancer, Hysterectomy, and Oophorectomy.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Alexandria University Hospitals

Residency

Jersey Shore University Medical Center

Specialties

Gynecologic Oncology
Oncology
Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in NJ

Board Certifications

American Board Of Obstetrics And Gynecology
American Board Of Obstetrics And Gynecology
American Board Of Obstetrics And Gynecology

Fellowships

Yale University School of Medicine
Lahey Clinic Medical Center

Hospital Affiliations

Ocean Medical Center
Riverview Medical Center
Southern Ocean Medical Center
Jfk University Medical Center
Jersey Shore University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

HMH - Obstetrics and Gynecology - Neptune
19 Davis Avenue, Floor 7, Neptune, NJ 7753.
Other Locations
1 Hospital Plaza, Suite 206, Old Bridge, NJ 8857.
HMH - Obstetrics and Gynecology - Forked River
730 Lacey Road, Suite 206, Forked River, NJ 8731.
1610 Route 88, Suite 203, Brick, NJ 8724.

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 6 Less Clinical Trials

18 Total Publications

Abdominal wall endometriosis in a caesarean section scar.
Abdominal wall endometriosis in a caesarean section scar.
Journal: BMJ case reports
Published: January 12, 2026
Similar Doctors
Mario Leitao
Expertise in
21
conditions
Dr. Mario Leitao
Gynecologic Oncology | Oncology
Expertise in
21
conditions
Dr. Mario Leitao
Gynecologic Oncology | Oncology

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (38.2 miles away)
914-229-2473
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mario Leitao is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Leitao is highly rated in 21 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Vaginal Cancer, Hysterectomy, and Lymphadenectomy. Dr. Leitao is currently accepting new patients.

Expertise in
32
conditions
Dr. Yukio Sonoda
Gynecologic Oncology | Oncology
Expertise in
32
conditions
Dr. Yukio Sonoda
Gynecologic Oncology | Oncology

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (38.2 miles away)
518-243-8840
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yukio Sonoda is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Sonoda is highly rated in 32 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Sonoda is currently accepting new patients.

Expertise in
29
conditions
Dr. Dennis Chi
Gynecologic Oncology | Oncology | General Surgery
Expertise in
29
conditions
Dr. Dennis Chi
Gynecologic Oncology | Oncology | General Surgery

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (38.2 miles away)
332-334-8553
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dennis Chi is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Chi is highly rated in 29 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Virilizing Ovarian Tumor, Oophorectomy, and Hysterectomy. Dr. Chi is currently accepting new patients.

Frequently Asked Questions about Dr. Karim S. Elsahwi

How do I make an appointment with Dr. Karim S. Elsahwi?

You can book an appointment with Dr. Karim S. Elsahwi by calling their office at 732-897-7944. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Karim S. Elsahwi a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Karim S. Elsahwi is classified as an Distinguished expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Karim S. Elsahwi specialize in?

While Dr. Karim S. Elsahwi is a Gynecologic Oncology, they have specific expertise in Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Ovarian Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gynecologic Oncology.

Does Dr. Karim S. Elsahwi participate in research or clinical trials?

Yes. Dr. Karim S. Elsahwi has published 18 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Karim S. Elsahwi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Karim S. Elsahwi accept my insurance?

Dr. Karim S. Elsahwi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 732-897-7944 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Elsahwi's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile